ET consists of 21 amino acids, and the N-terminal 15 residues are folded into a rigid loop by two sets of intrachain disulfide bonds. The presence of three endothelin-related genes and three products, ET-1, ET-2, and ET-3, has been reported [1, 2] . Subsequently, two subtypes of ET receptors, ET-A and ET-B, have been cloned and characterized [3, 4] . Since its discovery, ET has been shown to play an important role in the control of cardiovascular homeostasis [6] . The concentrations of ET-l-like immunoreactivity in plasma have also been reported to be increased in some cardiovascular disorders and renal failure, but the values of ET-1 were variable depending on the method used. The concentrations of ET-l in plasma are generally low, so high sensitivity and high specificity are required for an accurate immunoassay.
In previous assays, the lowest detection limit for ET-l concentration was 2 ng/L, which, in many cases, is higher than the ET-l concentration in normal human plasma; such assays, therefore, required preconcentration of samples before the assay. In addition, extraction of plasma samples with either silica cartridges or ET-l affinity beads has been needed to eliminate interference from other plasma constituents [7, 8] . Here we report our development of a method for direct determination of plasma ET-[, without any pretreatment steps, by using a highly sensitive chemiluminescence enzyme immunoassay (CLEIA) and confirm the reliability of the method. Use of this assay for rapid and accurate determination of plasma concentrations of ET-1 should lead to a better understanding of the peptide's pathophysiological role and clinical significance.
Materials and Methods Peptides and antibodies. The synthetic peptides ET-1, ET-3, and big ET-1 were purchased from Peptide Institute, Minoh, Japan.
Anti-ET(15-2l) rabbit IgG and Fab' fragment (of anti-ET-l rabbit IgG)-labeled horseradish peroxidase (HRP) were purchased from Immuno-Biological Labs., Fujioka, Japan.
Plasma samples. Blood was sampled from the antecubital veins of 37 apparently healthy subjects, ages 22-55 years, after an overnight fast. Additional blood samples from 15 patients with previous myocardial infarction, chronic heart failure, or chronic renal failure, who gave informed consent to extra blood sampling, were collected similarly, with the subjects in a recumbent position.
EDTA (2 g/L) and aprotinin (300 000 kIU/L) were added to the blood samples, which were then centrifuged at 1000g for 15 mm to separate plasma. The separated plasma samples were divided into small aliquots (0.5 mL/microtube) and stored at -80 #{176}C. Synthetic ET-1 diluted with the same buffer was used as the calibrator.
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Results
Assay range and detection limit. The calibration curve for measuring plasma ET-1 is linear over the range 0.5-20 ng/L (Fig. 1A) . The detection limit was determined to be 0.5 ng/L (0.05 pg/well); that is, we could discriminate the mean -25D (n = 6) lumicounts for 0.5 ng/L from the mean + 2SD for 0 ng/L ET-l (Fig. 1B) . (Table 1 ). In addition, a patient's sample containing 12.3 ngfL ET-1 showed no deviations from linearity after successive dilutions up to 32-fold (Fig.  2) . Mean 90.7 Plasma ET-1 concentration of normal subj ects. The arithmetic mean of the plasma ET-1 concentration for 37 presumably healthy subjects, as determined by this assay, was 0.65 ± 0.20 nglL.
Comparison with extraction procedure. Plasma ET-1 concentrations of 21 presumably healthy subjects were determined by both the direct assay without any extraction steps (the present method) and the same assay but with the extraction procedure (Fig. 3) . In samples with a low concentration of ET-1, both assays inherently have a large measurement error (20-30%). However, results by both methods were statistically significantly correlated (P <0.02).
Comparison with commercial kit. Plasma ET-I concentrations for 21 apparently healthy subjects and 14 patients with chronic renal failure were determined by both the present assay (direct method) and the commercial kit for plasma ET-1 (which requires extraction of samples; Wako Pure Chemical Industries, Osaka, Japan) (Fig. 4) . The comparison study showed r = 0.7 11 (P <0.0001) and a slope of 1.26. 
Discussion
The chemiluminescence immunoassay we have developed requires only 100 L of test sample to quantify plasma ET-1 and has a detection limit of 0.5 nglL (0.05 pg/well) of ET-l in plasma. This detection limit is four times as sensitive as that of a previously reported assay [7] . The high sensitivity of the present assay is mainly the result of our newly devised chemiluminescence reaction. We found that specific light emissions could be increased by adding a detergent with chemiluminescence enhancer and recrystallized luminol, and that background noise could be decreased by adding skim milk and egg albumin to the reaction [9] . The high sensitivity may also be attributable to the use of polyclonal antibodies. These populations of antibodies contain high-affinity antibodies and several epitopes against antigen. Brown et al. reported that the assay utilizing polyclonal antibody was more sensitive than that with monoclo- normal subjects and 14 patients with renal disorder. [11] .The results of the recovery test and the linearity of assay response of the diluted samples suggest low plasma interference in the present assay. Low plasma interference may also be aided by the high specificity of the antibody used to recognize ET-1 in our assays and also by modification of the dilution of test samples with the incubation buffer I in the assay. Because of the high sensitivity and low plasma interference in our method, we could establish a direct assay for plasma ET-l requiring no pretreatment steps. Our preliminary investigation revealed that the basal plasma ET-1 concentration in healthy subjects was 0.65 ± 0.20 ng/L, lower than previously reported [7] . This difference may result from a difference in the specificity or affinity of the antibodies used. Comparison studies showed the significant correlation between the present method and either the extraction procedure or the previous method (commercial kit), thus indicating the reliability of our assay. The rapid and sensitive determination of plasma ET-l concentrations will assist in the elucidation of the pathophysiological role and clinical significance of this peptide. It will also be useful in monitoring circulating ET-1 concentrations when antagonists of ET receptors are used in clinical trials.
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